Conmed CORP Form 4 insider transactions

CONMED Corporation's Director, Kim Kelderman, was granted 500 Restricted Stock Units and options to purchase 6,227 shares of common stock under the company's 2025 Long-Term Incentive Plan.

CONMED Corporation's Executive Vice President and CFO, Todd W. Garner, sold 598 shares of common stock at $52.45 per share.

CONMED Corporation's Director, Barbara J. Schwarzentraub, reported the acquisition of stock options and restricted stock units (RSUs) as part of her compensation, alongside the conversion of previously granted RSUs into common stock.

CONMED Corporation's Director Mark Kaye was granted 8,061 stock options and 668 restricted stock units under the company's 2025 Long-Term Incentive Plan.

CONMED Corporation Director Brian Concannon has reported the acquisition of new stock options and restricted stock units (RSUs), alongside the conversion of previously granted RSUs into common stock.

CONMED Corporation Director Charles Farkas has reported the acquisition of 8,061 stock options and 668 restricted stock units, alongside the conversion of 479 restricted stock units into common stock, as part of his compensation.

CONMED Corporation Director LaVerne H. Council has reported the acquisition of new stock options and restricted stock units (RSUs), alongside the conversion of existing RSUs into common stock.

CONMED Corporation Director David M. Bronson has reported the acquisition of 8,061 stock options and 668 restricted stock units (RSUs) under the company's 2025 Long-Term Incentive Plan, alongside the vesting and conversion of 479 RSUs into common stock.

CONMED Corporation Director Martha Goldberg Aronson has disclosed the acquisition of new stock options and restricted stock units, alongside the conversion of existing RSUs into common stock, as part of her compensation.

CONMED Corporation Director Charles Farkas exercised 1,000 Stock Appreciation Rights and subsequently sold 966 shares to cover tax liabilities, resulting in a net decrease in his direct common stock holdings.

Director John L. Workman reports a transaction involving CONMED Corp common stock and Restricted Stock Units (RSUs) on May 20, 2025.

Stephan Epinette, VP GM International at Conmed Corp, reports the settlement of vested restricted stock units (RSUs) resulting in the delivery of common stock shares.

Director Charles Farkas sold 4,000 shares of CONMED Corp stock at $56.942 per share on May 5, 2025.

Matthew Schabacker, VP GM Advanced Surgical at CONMED Corp, reports the acquisition of 31,675 stock options.

Todd W. Garner, Executive Vice President & CFO of CONMED Corp, recently acquired 371 shares of common stock at a price of $57.37 per share.

EVP Peter K. Shagory reports acquisition and disposal of CONMED Corp stock and stock appreciation rights on March 14, 2025.

Brent Lalomia, Vice President of QA and RA at Conmed Corp, reports the vesting and subsequent tax withholding related to restricted stock units.

Edward A. Clifford, VP Global Manufacturing at CONMED Corp, reports the acquisition of 26,127 stock options.

Hollie K. Foust, General Counsel & Corp Sec of CONMED Corp, reports the acquisition of 30,738 stock options.

Executive Vice President of HR at CONMED Corp, John D. Ferrell, reports the acquisition of 21,516 stock options.

Treasurer and VP of Tax at CONMED Corp, Johonna Marie Pelletier, reports the acquisition of 9,300 stock options.

Brent Lalomia, Vice President of QA and RA at CONMED Corp, reports the acquisition of 26,895 stock options on March 3, 2025, under the company's 2018 Long-Term Incentive Plan.

Richard Glaze, Chief Information Officer of CONMED Corp, reports the acquisition of 11,750 stock options.

Executive Vice President & CFO of CONMED Corp, Todd W. Garner, reports the acquisition of 61,475 stock options.

Peter K. Shagory, EVP of Strategy & Corporate Development at CONMED Corp, reports the acquisition of 26,127 stock options.

Director Mark Kaye reports acquisition of stock options and restricted stock units in CONMED Corp.

Richard Glaze, Chief Information Officer of CONMED Corp, reported the sale of 257 shares of common stock on February 11, 2025.

Andrew James Moller, VP Corporate Controller at CONMED Corp, was granted 5,000 stock options on January 27, 2025, under the company's 2018 Long-Term Incentive Plan.

CONMED Corp's CEO, Pat Beyer, was granted 86,355 stock options under the company's 2018 Long-Term Incentive Plan.

Richard Glaze, Chief Information Officer at Conmed Corp, reports the acquisition of 375 shares and disposal of 118 shares of common stock on November 20, 2024.